Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 3/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 8/20 | 0.33 |
| ▸ | TK1 | P04183 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18519852 | 0.79 | PNP (0.45) | PNPALDH1A1LMNAXDHTK1 | |
| SCHEMBL24239185 | 0.77 | PNP (0.46) | PNPALDH1A1XDHTK1 | |
| SCHEMBL23679550 | 0.76 | PNP (0.45) | PNPXDHTK1 | |
| SCHEMBL22901875 | 0.75 | PI4KA (0.41) | PNPPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18521164 | 0.75 | SMN1; SMN2 (0.51) | PNPPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18521156 | 0.75 | PNP (0.45) | PNPPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL23619480 | 0.74 | PNP (0.41) | PNPPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22381533 | 0.73 | PNP (0.42) | PNPALDH1A1LMNAXDHTK1 | |
| SCHEMBL5021598 | 0.72 | XDH (0.55) | PNPPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21637050 | 0.71 | TDP1 (0.37) | PI4KAPI4K2BPI4K2API4KBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11213592-B2 | Antibody-sting agonist conjugates and their use in immunotherapy | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210290774-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11033635-B2 | Antibody-STING agonist conjugates and their use in immunotherapy | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210015941-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213592-B2 | Antibody-sting agonist conjugates and their use in immunotherapy | STING1, CGAS, MAVS | PNP 917/4885PI4KA 1784/4885PI4K2B 2458/4885 |
| US-20210290774-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | STING1, CGAS, MAVS | PNP 917/4885PI4KA 1784/4885PI4K2B 2458/4885 |
| US-11033635-B2 | Antibody-STING agonist conjugates and their use in immunotherapy | STING1, CGAS, MAVS | PNP 917/4885PI4KA 1784/4885PI4K2B 2458/4885 |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | PNP 2979/4885PI4KA 3182/4885PI4K2B 3890/4885 |
| US-20210015941-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | STING1, CGAS, MAVS | PNP 917/4885PI4KA 1784/4885PI4K2B 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.